Teva Pharmaceuticals has discontinued its Phase 2 clinical trial of experimental drug emrusolmin in patients with multiple system atrophy (MSA), after an interim analysis found a low likelihood of the study achieving its primary efficacy target.

 

The decision to halt the TOPAS-MSA study follows a recommendation by an independent data monitoring committee (IDMC), which concluded that the trial had met its predefined futility criterion.

 

The interim predictive analysis indicated that continuing the study was unlikely to result in success against its primary efficacy endpoint. However, Teva stressed that the assessment was not a final analysis of the drug's efficacy.

 

Importantly, the company said no safety concerns were identified during the interim review.

 

Emrusolmin (TEV-'286), an investigational oral drug being developed in partnership with Germany-based MODAG GmbH, is designed to target alpha-synuclein aggregation, a key disease mechanism believed to contribute to MSA.

 

The setback does not, however, signal the end of the broader emrusolmin development programme.

 

Teva said it would undertake a comprehensive analysis of the TOPAS-MSA findings alongside available data from a separate open-label extension (OLE) study evaluating the drug in MSA patients. The company said the decision announced on November 2 applies specifically to the Phase 2 TOPAS-MSA trial and does not constitute a final decision on the overall programme.

 

“While we are disappointed by the outcome of this interim analysis for the Phase 2 study, we remain deeply committed to learning everything we can from these data,” said Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva.

 

“We are deeply grateful to the patients, families, investigators, and study teams who contributed their time and commitment to this research. Our hope is that the science and learnings can deepen our understanding of MSA and help us determine a path forward for emrusolmin.”

 

Teva said it would work with investigators to ensure study protocols are followed during the discontinuation process. The company also plans to present the findings to the scientific community once its comprehensive analysis is complete.

 

The TOPAS-MSA trial was a randomised, double-blind, placebo-controlled Phase 2 study designed to assess the safety and efficacy of emrusolmin in adults with multiple system atrophy.

 

The study was designed to enrol approximately 350 participants, who would receive either 300 mg of emrusolmin or a placebo for around 48 weeks, followed by a four-week follow-up period.

 

Its primary endpoint was the change from baseline to Week 48 in the modified Unified Multiple System Atrophy Rating Scale Part I score.

 

The separate open-label extension study was designed to assess the long-term safety and tolerability of emrusolmin in eligible participants who completed the 48-week treatment period.

 

According to Teva, MSA affects approximately 40,000 people across the United States, European Union and Japan, with around 6,000 new cases diagnosed annually. Life expectancy following diagnosis is generally six to 10 years.

 

Emrusolmin received Orphan Drug designation from the US Food and Drug Administration in 2022 and Fast Track designation in September 2025.

 

The drug's failure to clear the interim futility hurdle marks a setback for its clinical development. However, the forthcoming analysis of the trial and extension-study data will be crucial in determining whether Teva and its development partner can identify a viable path forward.